TAM | Jotup

Rivalry Reports Preliminary Fourth Quarter and Year-End 2023 Results

Retrieved on:

Friday, April 5, 2024

Rivalry is seeing a rise in demand to license its in-house casino games, accelerating the advancement of its B2B vertical.

Key Points:

Rivalry is seeing a rise in demand to license its in-house casino games, accelerating the advancement of its B2B vertical.
TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- Rivalry Corp. (the “Company” or “Rivalry”) (TSXV: RVLY) (OTCQX: RVLCF) (FSE: 9VK), the leading sportsbook and iGaming operator for Gen Z, today announced preliminary and unaudited financial results for the three and 12-month periods ended December 31, 2023.
“Rivalry exited 2023 as an increasingly diversified company – both geographically and across our product suite,” said Steven Salz, Co-Founder and CEO of Rivalry.
Management will host a conference call at 10:00 a.m. EDT on Friday, April 5, 2024 to discuss the Company’s preliminary unaudited year-end and fourth quarter 2023 financial results.

Canoo Enters a $30 Billion Market with Multiple Commercial Vehicle Sales in Saudi Arabia

Retrieved on:

Tuesday, April 2, 2024

EVS, Partnership, FTZ, Transport, Free-trade zone, KSA, Pleasure, Workflow, GCC, TAM, MENA, Crown, LDV, Gulf Cooperation Council, Renewable energy

Jazeera Paints will initially purchase 20 Canoo's electric vehicles (EVs) into its fleet in 2024, with the option to expand up to 180 additional vehicles.

Key Points:

Jazeera Paints will initially purchase 20 Canoo's electric vehicles (EVs) into its fleet in 2024, with the option to expand up to 180 additional vehicles.
This agreement taps into the Saudi Arabian EV market, which commands a total addressable market (TAM) of over $30 billion, and aligns with initiatives within the GCC region to enhance sustainable mobility solutions.
In addition, these electric commercial delivery vehicles provide Canoo with a first mover advantage in the Saudi market and a competitive position in the Gulf Cooperation Council (GCC) region.
Both companies anticipate this alliance will catalyze further innovation and collaboration, paving the way for a more sustainable and technologically advanced future in commercial transportation within the GCC and beyond.

Sapience Therapeutics Presents Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on:

Monday, April 8, 2024

Research, BCL9, MDSC, Survival, Patient, Wisdom, SVP, Neoplasm, The central science, Cancer, Macrophage, AP-1, IND, AACR, TAM, Phenotype, Therapy, Breast cancer, Poster, Cell, AP-1 transcription factor, TNBC, Metastasis, Vaccine

TARRYTOWN, N.Y., April 8, 2024 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced the presentation of new data on its clinical and pipeline programs during three poster presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024, in San Diego, CA.

Key Points:

We look forward to ST316 and ST101 continuing to advance through clinical development and moving our AP-1 program into IND-enabling studies."
Sapience scientists will present non-clinical immune-oncology results from both of its clinical programs, ST316, a first-in-class antagonist of β-catenin, and ST101, a first-in-class antagonist of C/EBPβ.
In nonclinical studies, Sapience evaluated the ability of ST316 to enhance anti-tumor immune responses in combination with anti-PD-1 and anti-TIGIT therapies.
JunAP demonstrates potent anti-tumor activity in vivo in mouse triple negative breast cancer and melanoma tumor models.

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on:

Monday, March 25, 2024

CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points:

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

Distinguished Programs Partners with Higginbotham as the Preferred Insurance Provider for the Texas Association of Museums

Retrieved on:

Tuesday, April 2, 2024

Legal, Professional Services, Human Resources, Finance, Partnership, Library, Transport, Insurance, TAM, Heart, Texas Association, Multimedia, Tourism

Distinguished Programs (“Distinguished”), a leading insurance program manager, is excited to announce a new partnership agreement with Higginbotham to act as the preferred provider for the Texas Association of Museums (“TAM”).

Key Points:

Distinguished Programs (“Distinguished”), a leading insurance program manager, is excited to announce a new partnership agreement with Higginbotham to act as the preferred provider for the Texas Association of Museums (“TAM”).
This alliance marks a dedicated effort to craft tailor-made insurance solutions for museums in Texas.
View the full release here: https://www.businesswire.com/news/home/20240402548078/en/
Distinguished Programs Partners with Higginbotham as the Preferred Insurance Provider for the Texas Association of Museums.
"Our collaboration with Higginbotham amplifies our ability to provide bespoke insurance offerings, ensuring Texas museums have the protection they need to preserve their legacies."

Movano Health Reports 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, April 4, 2024

PLEASANTON, Calif., April 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported fourth quarter and year end 2023 results and provided a business update.

Key Points:

PLEASANTON, Calif., April 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, reported fourth quarter and year end 2023 results and provided a business update.
Movano Health achieved significant development milestones on its path to obtaining the FDA clearances necessary to launch the medical device version of the ring, Evie Med.
In October 2023, announced the results of its Institutional Review Board (IRB)-approved blood pressure clinical study.
Management will host a conference call and live audio webcast to discuss these results and provide a business update today at 2:00 pm PT/5:00 pm ET.

Demand for Real-time AI Inference from Groq® Accelerates Week Over Week

Retrieved on:

Tuesday, April 2, 2024

Conservative Party (United States), HBM, SRAM, Government, GPU, Tensor, CUDA, Memory, Risk, Human, Running, AI, Software, Heat, Life, Carbon, Abstract, Architecture, Graphics processing unit, TAM, API, Economics, LPU, Plague, Video game

MOUNTAIN VIEW, Calif., April 2, 2024 /PRNewswire/ -- Groq®, a generative AI solutions company, announced today that more than 70,000 new developers are using GroqCloud™and more than 19,000 new applications are running on the LPU™ Inference Engine via the Groq API. The rapid migration to GroqCloud since its launch on March 1st indicates a clear demand for real-time inference as developers and companies seek lower latency and greater throughput for their generative and conversational AI applications.

Key Points:

It's clear that developers are hungry for low-latency AI inference capabilities, and we're thrilled to see how it's being used to bring innovative ideas to life.
Today, ~40% of AI chips are leveraged for inference, and that alone would put the TAM for chips used for inference at ~$48B by 2027.
Once applications reach maturity they often allocate 90-95 percent of resources to inference, indicating a much larger market over time.
With nearly every industry and government worldwide looking to leverage generative and/or conversational AI, the TAM for AI chips, and systems dedicated to inference in particular, appears to be limitless.

Ballistic Ventures Closes $360 Million Oversubscribed Fund II to Fuel the Next Generation of Cybersecurity Innovation

Retrieved on:

Thursday, March 14, 2024

Financial management, Organization, McKinsey & Company, Software as a service, Growth, Palo Alto Networks, Philosophy, Alethea, Partnership, SAN, Head, Knowledge, PitchBook Data, Running, Acquisition, AI, Kleiner Perkins, TAM

SAN FRANCISCO, March 14, 2024 /PRNewswire/ -- Ballistic Ventures today announced the close of its oversubscribed $360 million second fund.

Key Points:

SAN FRANCISCO, March 14, 2024 /PRNewswire/ -- Ballistic Ventures today announced the close of its oversubscribed $360 million second fund.
Fund II for Ballistic Ventures reinforces its commitment to exclusively fund and incubate entrepreneurs and innovations shaping the future of our cybersecurity.
Ballistic Ventures closes its oversubscribed $360M second fund.
In a sector with promising tailwinds, Ballistic Ventures is set apart by the expertise of its team.

Sovrn Signal Delivers 10% Revenue Uplift

Retrieved on:

Wednesday, March 13, 2024

Mumsnet, Canadian Tire money, Amazon, Intelligence, SSPS, Head, GAM, Daily Voice, TAM, CPM, Privacy, Parent, SSP, Mobile phone

BOULDER, Colo., March 13, 2024 /PRNewswire/ -- Sovrn, a publisher technology platform that helps content creators earn and keep more revenue, today announced that Sovrn's Signal product has proven to deliver a 10% revenue uplift. Over a 90-day period starting in December 2023 across 8 billion auctions, with publishers representing 190 domains, testing proved that Signal delivered an unmatched ability to create higher yields, increased CPMs, and greater programmatic revenue across multiple SSPs.

Key Points:

BOULDER, Colo., March 13, 2024 /PRNewswire/ -- Sovrn , a publisher technology platform that helps content creators earn and keep more revenue, today announced that Sovrn's Signal product has proven to deliver a 10% revenue uplift.
Steady revenue uplift even amid traffic spikes, dips, and cyclical demand trends.
In addition, publishers have the option to bundle the Sovrn Ad Exchange to receive a zero percent take rate on impressions sent through the Sovrn Exchange.
"At Sovrn, we are always looking for opportunities to help publishers capture higher revenue from their quality content, which is why we created Signal in the first place," said Babac Vafaey, vice president of data products at Sovrn.

Leatt Corp Announces Results for Fourth Quarter and Full Year 2023

Retrieved on:

Wednesday, March 13, 2024

Growth, Environment, Webcast, MTB, Moto, EICMA, TAM, ADV, OTCQB, All, Marketing, Hand, Total, Video game

Fourth quarter 2023 revenues were $9.80 million, down 10% compared to 2022.

Key Points:

Fourth quarter 2023 revenues were $9.80 million, down 10% compared to 2022.
"Revenues for the fourth quarter of 2023 were $9.80 million, a 10% decrease when compared to the 2022 fourth quarter.
Total revenues for the fourth quarter of 2023 were $9.80 million, down 10%, compared to $10.91 million for the fourth quarter of 2022.
The Company will host a conference call at 10:00 am ET on Wednesday, March 13, 2024, to discuss the 2023 fourth quarter and full-year results.